Download MendeleyNms-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity in Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases.
Fogliatto, G., Gianellini, L.M., Brasca, M.G., Casale, E., Ballinari, D., Ciomei, M., Degrassi, A., De Ponti, A., Germani, M., Guanci, M., Paolucci, M., Polucci, P., Russo, M., Sola, F., Valsasina, B., Visco, C., Zuccotto, F., Donati, D., Felder, E., Pesenti, E., Mantegani, S., Galvani, A., Isacchi, A.(2013) Clin Cancer Res 19: 3520
- PubMed: 23674492
- DOI: https://doi.org/10.1158/1078-0432.CCR-12-3512
- Primary Citation of Related Structures:
4B7P - PubMed Abstract:
Recent developments of second generation Hsp90 inhibitors suggested a potential for development of this class of molecules also in tumors that have become resistant to molecular targeted agents. Disease progression is often due to brain metastases, sometimes related to insufficient drug concentrations within the brain. Our objective was to identify and characterize a novel inhibitor of Hsp90 able to cross the blood-brain barrier (BBB). Here is described a detailed biochemical and crystallographic characterization of NMS-E973. Mechanism-based anticancer activity was described in cell models, including models of resistance to kinase inhibitors. Pharmacokinetics properties were followed in plasma, tumor, liver, and brain. In vivo activity and pharmacodynamics, as well as the pharmacokinetic/pharmacodynamic relationships, were evaluated in xenografts, including an intracranially implanted melanoma model. NMS-E973, representative of a novel isoxazole-derived class of Hsp90 inhibitors, binds Hsp90α with subnanomolar affinity and high selectivity towards kinases, as well as other ATPases. It possesses potent antiproliferative activity against tumor cell lines and a favorable pharmacokinetic profile, with selective retention in tumor tissue and ability to cross the BBB. NMS-E973 induces tumor shrinkage in different human tumor xenografts, and is highly active in models of resistance to kinase inhibitors. Moreover, consistent with its brain penetration, NMS-E973 is active also in an intracranially implanted melanoma model. Overall, the efficacy profile of NMS-E973 suggests a potential for development in different clinical settings, including tumors that have become resistant to molecular targeted agents, particularly in cases of tumors which reside beyond the BBB.
Organizational Affiliation:
Department of Biotechnology, Nerviano Medical Sciences Srl, Nerviano (MI), Italy. gianpaolo.fogliatto@nervianoms.com
